multivalent bi-specific nanobioconjugate engager (Mayo Clinic)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namemultivalent bi-specific nanobioconjugate engager (Mayo Clinic)

Drug Alias NamemBiNE (Mayo Clinic)Tumor-targeted immunotherapy (Mayo Clinic)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsCalreticulin modulators

TargetsReceptor protein-tyrosine kinase erbB-2Calreticulin

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMayo Clinic

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMayo Clinic

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A